Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 14/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 3/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.61 |
| ▸ | HTR6 | P50406 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194535 | 0.93 | POLB (0.74) | HTR7POLBHTR1AADRA2AHTR6 | |
| SCHEMBL6340577 | 0.88 | HTR7 (0.70) | HTR7POLBALDH1A1HTR1AADRA2A | |
| SCHEMBL6337236 | 0.87 | HTR7 (0.68) | HTR7POLBALDH1A1HTR1AADRA2A | |
| SCHEMBL29172771 | 0.84 | HTR7 (0.60) | HTR7ALDH1A1HTR6PKM | |
| SCHEMBL24069077 | 0.82 | HTR7 (0.87) | HTR7POLBALDH1A1HTR1AADRA2A | |
| SCHEMBL25758471 | 0.81 | HTR7 (0.60) | HTR7POLBALDH1A1HTR1AADRA2A | |
| SCHEMBL6338842 | 0.81 | POLB (0.80) | HTR7POLBHTR1AADRA2AHTR6 | |
| SCHEMBL29991400 | 0.80 | KMT2A (0.62) | HTR7POLBALDH1A1HTR1AHTR6 | |
| SCHEMBL6341348 | 0.80 | POLB (0.74) | HTR7POLBHTR1AADRA2AHTR6 | |
| SCHEMBL7426154 | 0.79 | HTR7 (0.61) | HTR7POLBALDH1A1HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | HTR7 805/4885POLB 4356/4885ALDH1A1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.